NASDAQ:VBIV - VBI Vaccines News Headlines

Sign in or create an account to add this stock to your watchlist.
$1.97 0.00 (0.00 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.97
Today's Range$1.9240 - $2.0001
52-Week Range$1.14 - $4.16
Volume182,987 shs
Average Volume342,305 shs
Market Capitalization$192.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27

Headlines

VBI Vaccines (NASDAQ VBIV) News Headlines

Source:
DateHeadline
VBI Vaccines, Inc. Estimate MomentumVBI Vaccines, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 4:58 PM
VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare ConferenceVBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
finance.yahoo.com - March 18 at 10:06 AM
Analyzing VBI Vaccines (VBIV) and Its CompetitorsAnalyzing VBI Vaccines (VBIV) and Its Competitors
www.americanbankingnews.com - March 4 at 9:28 PM
Reviewing VBI Vaccines (VBIV) & Its RivalsReviewing VBI Vaccines (VBIV) & Its Rivals
www.americanbankingnews.com - March 4 at 7:28 PM
Short Interest in VBI Vaccines Inc (VBIV) Decreases By 43.6%Short Interest in VBI Vaccines Inc (VBIV) Decreases By 43.6%
www.americanbankingnews.com - March 4 at 1:45 AM
Q3 2019 Earnings Forecast for VBI Vaccines Inc Issued By Oppenheimer (VBIV)Q3 2019 Earnings Forecast for VBI Vaccines Inc Issued By Oppenheimer (VBIV)
www.americanbankingnews.com - March 1 at 6:05 PM
VBI Vaccines Inc (VBIV) Expected to Announce Quarterly Sales of $2.13 MillionVBI Vaccines Inc (VBIV) Expected to Announce Quarterly Sales of $2.13 Million
www.americanbankingnews.com - February 28 at 1:08 AM
VBI Vaccines (VBIV) PT Set at $9.00 by OppenheimerVBI Vaccines (VBIV) PT Set at $9.00 by Oppenheimer
www.americanbankingnews.com - February 27 at 12:52 AM
Key data readout mid-year for VBIs Hep B vaccineKey data readout mid-year for VBI's Hep B vaccine
seekingalpha.com - February 26 at 4:54 PM
VBI Vaccines (VBIV) Issues Quarterly  Earnings Results, Misses Expectations By $0.09 EPSVBI Vaccines (VBIV) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - February 26 at 7:34 AM
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results - GlobeNewswireVBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results - GlobeNewswire
globenewswire.com - February 25 at 5:01 PM
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial ResultsVBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
finance.yahoo.com - February 25 at 10:56 AM
VBI GBM study of VBI-1901 to continue; shares up 3% premarketVBI GBM study of VBI-1901 to continue; shares up 3% premarket
seekingalpha.com - February 7 at 10:28 AM
VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM PatientsVBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
finance.yahoo.com - February 7 at 10:28 AM
VBI Vaccines Appoints Blaine McKee to Board of DirectorsVBI Vaccines Appoints Blaine McKee to Board of Directors
finance.yahoo.com - January 16 at 10:00 AM
Form 8-K VBI Vaccines Inc/BC For: Dec 18 - StreetInsider.comForm 8-K VBI Vaccines Inc/BC For: Dec 18 - StreetInsider.com
www.streetinsider.com - December 21 at 9:16 AM
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate - GlobeNewswireVBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate - GlobeNewswire
globenewswire.com - December 21 at 9:16 AM
VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine CandidateVBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
finance.yahoo.com - December 20 at 9:34 AM
VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 MillionVBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million
finance.yahoo.com - December 18 at 9:41 AM
VBI Vaccines Announces Pricing of $37.5 Million Public OfferingVBI Vaccines Announces Pricing of $37.5 Million Public Offering
finance.yahoo.com - December 13 at 5:13 PM
VBI Vaccines Announces Proposed Public Offering of Common SharesVBI Vaccines Announces Proposed Public Offering of Common Shares
finance.yahoo.com - December 12 at 5:04 PM
Form 8-K VBI Vaccines Inc/BC For: Dec 04 - StreetInsider.comForm 8-K VBI Vaccines Inc/BC For: Dec 04 - StreetInsider.com
www.streetinsider.com - December 6 at 9:07 AM
VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis BVBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B
finance.yahoo.com - December 6 at 9:07 AM
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate UpdateVBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 9:34 AM
Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and ...Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and ...
globenewswire.com - October 25 at 4:45 PM
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
finance.yahoo.com - October 24 at 8:47 AM
VBI Vaccines (VBIV) Reports Complete Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac Hepatitis B VaccineVBI Vaccines (VBIV) Reports Complete Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac Hepatitis B Vaccine
www.streetinsider.com - October 17 at 8:49 AM
Vaccinations completed in VBIs late-stage study for Sci-B-VacVaccinations completed in VBI's late-stage study for Sci-B-Vac
seekingalpha.com - October 16 at 4:40 PM
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B VaccineVBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
finance.yahoo.com - October 16 at 9:00 AM
VBI Vaccines (VBIV) Announces Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeekVBI Vaccines (VBIV) Announces Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek
www.streetinsider.com - October 3 at 8:47 AM
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
finance.yahoo.com - October 2 at 8:50 AM
VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceVBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 27 at 9:11 AM
VBI Vaccines Announces Formation of New Scientific and Clinical Advisory BoardsVBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards
finance.yahoo.com - September 26 at 9:16 AM
VBI Vaccines (VBIV) Reports Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) PatientsVBI Vaccines (VBIV) Reports Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
www.streetinsider.com - September 25 at 8:43 AM
VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) PatientsVBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
finance.yahoo.com - September 25 at 8:43 AM
VBI Vaccines takes issue with critical news articleVBI Vaccines takes issue with critical news article
seekingalpha.com - September 17 at 9:15 AM
Join Perceptive Advisors And Buy VBI Vaccines At $2 NowJoin Perceptive Advisors And Buy VBI Vaccines At $2 Now
seekingalpha.com - September 10 at 10:11 AM
New finance chief at VBI VaccinesNew finance chief at VBI Vaccines
seekingalpha.com - August 15 at 4:44 PM
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business DevelopmentVBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
finance.yahoo.com - August 15 at 9:08 AM
VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth ConferenceVBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference
finance.yahoo.com - August 6 at 4:46 PM
VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate UpdateVBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - July 26 at 9:17 AM
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight SummitVBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
finance.yahoo.com - July 9 at 8:52 AM
VBI Vaccines to Present at 2018 JMP Securities Life Sciences ConferenceVBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference
finance.yahoo.com - June 19 at 10:58 AM
Reader Inquiry: VBI Vaccines´ CEO Is Buying Shares, Should You?Reader Inquiry: VBI Vaccines´ CEO Is Buying Shares, Should You?
seekingalpha.com - May 27 at 9:02 AM
VBI Vaccines Announces Results of Annual General MeetingVBI Vaccines Announces Results of Annual General Meeting
finance.yahoo.com - May 25 at 4:43 PM
Health Care Sector Update for 05/22/2018: VBIV,CTMX,RDY,BMRNHealth Care Sector Update for 05/22/2018: VBIV,CTMX,RDY,BMRN
www.nasdaq.com - May 23 at 4:41 PM
VBI Vaccines (VBIV) Outlines Clinical Trial ProgressVBI Vaccines (VBIV) Outlines Clinical Trial Progress
www.streetinsider.com - May 22 at 4:43 PM
Well Leveraged: VBI Vaccines Outlines Clinical Trial ProgressWell Leveraged: VBI Vaccines Outlines Clinical Trial Progress
finance.yahoo.com - May 22 at 4:43 PM
VBI Vaccines (VBIV) CMV Vaccine VBI - 1501A Final Phase I Data - SlideshowVBI Vaccines (VBIV) CMV Vaccine VBI - 1501A Final Phase I Data - Slideshow
seekingalpha.com - May 11 at 4:52 PM
UPDATE: VBI Vaccines (VBIV) PT Raised to $13 at BMO CapitalUPDATE: VBI Vaccines (VBIV) PT Raised to $13 at BMO Capital
www.streetinsider.com - May 10 at 4:43 PM
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel